Literature DB >> 29558786

Amiodarone-Induced Thyroid Dysfunction: A Clinical Update.

Mohamed Nabil Elnaggar1,2, Kahtan Jbeili1, Nik Nik-Hussin3, Mohandas Kozhippally4, Joseph M Pappachan1.   

Abstract

Amiodarone is one of the most commonly prescribed antiarrhythmic agents in clinical practice owing to its efficacy, even with high toxicity profile. The high iodine content and the prolonged biological half-life of the drug can result in thyroid dysfunction in a high proportion of patients treated with amiodarone even after cessation of amiodarone. Both hypothyroidism and hyperthyroidism are common side effects that mandate regular monitoring of patients with thyroid function tests. Amiodarone-induced hypothyroidism (AIH) is diagnosed and managed in the same way as a usual case of hypothyroidism. However, differential diagnosis and clinical management of amiodarone-induced thyrotoxicosis (AIT) subtypes can be challenging. With the aid of a case snippet, we update the current evidence for the diagnostic work up and management of patients with amiodarone-induced thyroid dysfunction in this article. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29558786     DOI: 10.1055/a-0577-7574

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  3 in total

1.  AMIODARONE-INDUCED THYROTOXICOSIS AFTER TOTAL THYROIDECTOMY FOR METASTATIC FOLLICULAR THYROID CANCER.

Authors:  Christerlyn Charles; Ketan K Dhatariya
Journal:  AACE Clin Case Rep       Date:  2019-12-20

2.  Sudden cardiac arrest associated with myxedema coma due to undiagnosed hypothyroidism: a case report.

Authors:  Asami Yoshinaka; Masayuki Akatsuka; Shuji Yamamoto; Michiaki Yamakage
Journal:  BMC Endocr Disord       Date:  2021-11-17       Impact factor: 2.763

3.  Amiodarone-Induced Thyrotoxicosis - Literature Review & Clinical Update.

Authors:  Luciana Vergara Ferraz de Souza; Maria Thereza Campagnolo; Luiz Claudio Behrmann Martins; Maurício Ibrahim Scanavacca
Journal:  Arq Bras Cardiol       Date:  2021-11       Impact factor: 2.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.